Cargando…
Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”—Outcome Report of 92 Patients
(1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD t...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952775/ https://www.ncbi.nlm.nih.gov/pubmed/31817480 http://dx.doi.org/10.3390/cells8121577 |
_version_ | 1783486498130100224 |
---|---|
author | Bonig, Halvard Kuçi, Zyrafete Kuçi, Selim Bakhtiar, Shahrzad Basu, Oliver Bug, Gesine Dennis, Mike Greil, Johann Barta, Aniko Kállay, Krisztián M. Lang, Peter Lucchini, Giovanna Pol, Raj Schulz, Ansgar Sykora, Karl-Walter Teichert von Luettichau, Irene Herter-Sprie, Grit Ashab Uddin, Mohammad Jenkin, Phil Alsultan, Abdulrahman Buechner, Jochen Stein, Jerry Kelemen, Agnes Jarisch, Andrea Soerensen, Jan Salzmann-Manrique, Emilia Hutter, Martin Schäfer, Richard Seifried, Erhard Paneesha, Shankara Novitzky-Basso, Igor Gefen, Aharon Nevo, Neta Beutel, Gernot Schlegel, Paul-Gerhardt Klingebiel, Thomas Bader, Peter |
author_facet | Bonig, Halvard Kuçi, Zyrafete Kuçi, Selim Bakhtiar, Shahrzad Basu, Oliver Bug, Gesine Dennis, Mike Greil, Johann Barta, Aniko Kállay, Krisztián M. Lang, Peter Lucchini, Giovanna Pol, Raj Schulz, Ansgar Sykora, Karl-Walter Teichert von Luettichau, Irene Herter-Sprie, Grit Ashab Uddin, Mohammad Jenkin, Phil Alsultan, Abdulrahman Buechner, Jochen Stein, Jerry Kelemen, Agnes Jarisch, Andrea Soerensen, Jan Salzmann-Manrique, Emilia Hutter, Martin Schäfer, Richard Seifried, Erhard Paneesha, Shankara Novitzky-Basso, Igor Gefen, Aharon Nevo, Neta Beutel, Gernot Schlegel, Paul-Gerhardt Klingebiel, Thomas Bader, Peter |
author_sort | Bonig, Halvard |
collection | PubMed |
description | (1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD treatment with immunosuppressive agents as these predispose patients to opportunistic infections and loss of graft-versus-leukemia surveillance resulting in relapse. Mesenchymal stromal cells (MSC) from different tissues and those generated by various protocols have been proposed as a remedy for R-aGvHD but the enthusiasm raised by initial reports has not been ubiquitously reproduced. (2) Methods: We previously reported on a unique MSC product, which was generated from pooled bone marrow mononuclear cells of multiple third-party donors. The products showed dose-to-dose equipotency and greater immunosuppressive capacity than individually expanded MSCs from the same donors. This product, MSC-FFM, has entered clinical routine in Germany where it is licensed with a national hospital exemption authorization. We previously reported satisfying initial clinical outcomes, which we are now updating. The data were collected in our post-approval pharmacovigilance program, i.e., this is not a clinical study and the data is high-level and non-monitored. (3) Results: Follow-up for 92 recipients of MSC-FFM was reported, 88 with GvHD ≥°III, one-third only steroid-refractory and two-thirds therapy resistant (refractory to steroids plus ≥2 additional lines of treatment). A median of three doses of MSC-FFM was administered without apparent toxicity. Overall response rates were 82% and 81% at the first and last evaluation, respectively. At six months, the estimated overall survival was 64%, while the cumulative incidence of death from underlying disease was 3%. (4) Conclusions: MSC-FFM promises to be a safe and efficient treatment for severe R-aGvHD. |
format | Online Article Text |
id | pubmed-6952775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69527752020-01-23 Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”—Outcome Report of 92 Patients Bonig, Halvard Kuçi, Zyrafete Kuçi, Selim Bakhtiar, Shahrzad Basu, Oliver Bug, Gesine Dennis, Mike Greil, Johann Barta, Aniko Kállay, Krisztián M. Lang, Peter Lucchini, Giovanna Pol, Raj Schulz, Ansgar Sykora, Karl-Walter Teichert von Luettichau, Irene Herter-Sprie, Grit Ashab Uddin, Mohammad Jenkin, Phil Alsultan, Abdulrahman Buechner, Jochen Stein, Jerry Kelemen, Agnes Jarisch, Andrea Soerensen, Jan Salzmann-Manrique, Emilia Hutter, Martin Schäfer, Richard Seifried, Erhard Paneesha, Shankara Novitzky-Basso, Igor Gefen, Aharon Nevo, Neta Beutel, Gernot Schlegel, Paul-Gerhardt Klingebiel, Thomas Bader, Peter Cells Article (1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD treatment with immunosuppressive agents as these predispose patients to opportunistic infections and loss of graft-versus-leukemia surveillance resulting in relapse. Mesenchymal stromal cells (MSC) from different tissues and those generated by various protocols have been proposed as a remedy for R-aGvHD but the enthusiasm raised by initial reports has not been ubiquitously reproduced. (2) Methods: We previously reported on a unique MSC product, which was generated from pooled bone marrow mononuclear cells of multiple third-party donors. The products showed dose-to-dose equipotency and greater immunosuppressive capacity than individually expanded MSCs from the same donors. This product, MSC-FFM, has entered clinical routine in Germany where it is licensed with a national hospital exemption authorization. We previously reported satisfying initial clinical outcomes, which we are now updating. The data were collected in our post-approval pharmacovigilance program, i.e., this is not a clinical study and the data is high-level and non-monitored. (3) Results: Follow-up for 92 recipients of MSC-FFM was reported, 88 with GvHD ≥°III, one-third only steroid-refractory and two-thirds therapy resistant (refractory to steroids plus ≥2 additional lines of treatment). A median of three doses of MSC-FFM was administered without apparent toxicity. Overall response rates were 82% and 81% at the first and last evaluation, respectively. At six months, the estimated overall survival was 64%, while the cumulative incidence of death from underlying disease was 3%. (4) Conclusions: MSC-FFM promises to be a safe and efficient treatment for severe R-aGvHD. MDPI 2019-12-05 /pmc/articles/PMC6952775/ /pubmed/31817480 http://dx.doi.org/10.3390/cells8121577 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bonig, Halvard Kuçi, Zyrafete Kuçi, Selim Bakhtiar, Shahrzad Basu, Oliver Bug, Gesine Dennis, Mike Greil, Johann Barta, Aniko Kállay, Krisztián M. Lang, Peter Lucchini, Giovanna Pol, Raj Schulz, Ansgar Sykora, Karl-Walter Teichert von Luettichau, Irene Herter-Sprie, Grit Ashab Uddin, Mohammad Jenkin, Phil Alsultan, Abdulrahman Buechner, Jochen Stein, Jerry Kelemen, Agnes Jarisch, Andrea Soerensen, Jan Salzmann-Manrique, Emilia Hutter, Martin Schäfer, Richard Seifried, Erhard Paneesha, Shankara Novitzky-Basso, Igor Gefen, Aharon Nevo, Neta Beutel, Gernot Schlegel, Paul-Gerhardt Klingebiel, Thomas Bader, Peter Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”—Outcome Report of 92 Patients |
title | Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”—Outcome Report of 92 Patients |
title_full | Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”—Outcome Report of 92 Patients |
title_fullStr | Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”—Outcome Report of 92 Patients |
title_full_unstemmed | Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”—Outcome Report of 92 Patients |
title_short | Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation “MSC-FFM”—Outcome Report of 92 Patients |
title_sort | children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation “msc-ffm”—outcome report of 92 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952775/ https://www.ncbi.nlm.nih.gov/pubmed/31817480 http://dx.doi.org/10.3390/cells8121577 |
work_keys_str_mv | AT bonighalvard childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT kucizyrafete childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT kuciselim childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT bakhtiarshahrzad childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT basuoliver childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT buggesine childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT dennismike childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT greiljohann childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT bartaaniko childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT kallaykrisztianm childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT langpeter childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT lucchinigiovanna childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT polraj childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT schulzansgar childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT sykorakarlwalter childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT teichertvonluettichauirene childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT herterspriegrit childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT ashabuddinmohammad childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT jenkinphil childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT alsultanabdulrahman childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT buechnerjochen childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT steinjerry childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT kelemenagnes childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT jarischandrea childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT soerensenjan childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT salzmannmanriqueemilia childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT huttermartin childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT schaferrichard childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT seifriederhard childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT paneeshashankara childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT novitzkybassoigor childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT gefenaharon childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT nevoneta childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT beutelgernot childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT schlegelpaulgerhardt childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT klingebielthomas childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients AT baderpeter childrenandadultswithrefractoryacutegraftversushostdiseaserespondtotreatmentwiththemesenchymalstromalcellpreparationmscffmoutcomereportof92patients |